Dr. Manos Perros (Chairman)

Dr. Manos Perros is a renowned antimicrobial drug hunter with 28 years of industry experience. Currently, he serves as Executive Chairman of the Board at Venatorx Pharmaceuticals (2024-present) and Chairman of the Advisory Board at Aurobac Therapeutics (2023-present). As President, CEO, and co-founder of Entasis Therapeutics (2015-2022), he led the development of Xacduro, the first FDA-approved treatment for Acinetobacter baumannii pneumonia. His previous roles include Head of Infection and Site Head at AstraZeneca’s Boston R&D (2010-2015), Director of Novartis Institute for Tropical Diseases (2010), and Vice President & CSO of Antivirals at Pfizer (1996-2010), where he helped develop Selzentry, a first-in-class HIV treatment.